Passage Bio to Present New Data on Gene Therapy for Frontotemporal Dementia at ISFTD2024
Portfolio Pulse from Benzinga Newsdesk
Passage Bio, Inc. (NASDAQ:PASG) will present new data on its gene therapy PBFT02 for frontotemporal dementia at ISFTD2024. The data from the Phase 1/2 upliFT-D trial shows promising safety and biomarker results, with no serious adverse events reported.
September 16, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Passage Bio's presentation of positive Phase 1/2 trial data for PBFT02 at ISFTD2024 could boost investor confidence. The data shows robust increases in CSF PRGN expression and no serious adverse events, highlighting the therapy's potential.
The presentation of positive trial data at a major conference is likely to increase investor confidence in Passage Bio's PBFT02 therapy. The absence of serious adverse events and the potential for the therapy to be best-in-class are significant factors that could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100